Statins for Prostate Cancer: When and How Much?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 34281913.
- Also identified by DOI 10.1158/1078-0432.CCR-21-1891.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Statins have plausible biological effects against prostate cancer cells and are associated with improved disease-specific mortality. In current randomized placebo-controlled trial, low-dose atorvastatin caused no difference in relapses after radical prostatectomy in Asian men. Future trials should study higher statin doses at later disease stages with survival as the endpoint.<i>See related article by Jeong et al., p. 5004</i>.
Medical subject headings
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Prostatic Neoplasms